Comparative Pharmacology
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PEN VEE K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PEN VEE K.
DICLOXACILLIN SODIUM vs PEN-VEE K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicloxacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and leading to cell lysis. It is resistant to penicillinase-producing organisms.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
125-500 mg orally every 6 hours
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates, elderly, or severe renal impairment.
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Primarily renal: ~60-85% unchanged via glomerular filtration and tubular secretion; ~10% hepatobiliary (bile) and fecal; minor metabolism to penicilloic acid.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic